Aclaris attracts $21 mln Series B
Aclaris Therapeutics said Thursday that it has received $21 million in Series B financing. The investors were return backers Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Based in Malvern, Penn., Aclaris Therapeutics is a specialty pharmaceutical firm focused on developing a treatment that removes various skin lesions.
2 October 2014•4 mins read
